News

Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.

This year’s event will offer attendees both new and returning special events and features.

Ophthalmology Times® talked with Darius Moshfeghi, MD, about BUTTERFLEYE data trial results using aflibercept versus laser for the treatment of retinopathy of prematurity this year's ARVO meeting.

Efavirenz boosts cholesterol turnover in retina, brain.

Ophthalmology Times® talked with Mary Durbin, PhD, about a convolutional neural network that provides image quality assessment at this year's ARVO meeting.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked Nevin El-Nimri, MS, OD, PhD, FAAO, about the relationship between optic disc fovea distance, axial length and disc at this year's ARVO meeting.

FDA has cleared Atsena Therapeutics' Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS).

Kiora Pharmaceuticals presented preliminary results for its investigational drug, KIO-301, a light-sensing small molecule designed to reactivate visual function of the eye in response to light.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

Astellas Pharma has agreed to acquire Iveric Bio for a reported $5.9 billion (USD) with the goal of continuing progress in the innovation of ophthalmic therapeutics.

In a question and answer session, four leading ophthalmologists share their experiences with crosslinking, offering pearls that can help peers incorporate the procedure into their practice.

Iveric Bio has promising programs including avacincaptad pegol, an important program for geographic atrophy secondary to age-related macular degeneration with a. PDUFA goal data of August 19.

Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

Physician outlines latest emerging technologies to treat condition

The presentations highlighted the Clearside Biomedical’s efforts in suprachoroidal delivery of agents to the back of the eye.

Kaushal Solanki, PhD, CEO and founder of Eyenuk, shared news about the company's EyeArt AI, which is cleared by the FDA to detect diabetic retinopathy.

The UCL-Moorfields team have developed a deep learning AI model to screen for ROP, which was trained on a sample of 7,414 images of the eyes of 1,370 newborns who had been admitted to the Homerton Hospital, London, and assessed for ROP by ophthalmologists.

Glaucoma specialists nationwide reported that glaucoma-related adverse events were common after cataract surgery in children.

Managing health data as non-fungible tokens could give patients full ownership of personal health data, resulting in better patient care and research outcomes.

Ophthalmology Times® talked with Theresa Heath, MD, MBA, about Non-viral gene therapy targeting ABCA4 retinopathies at this year's ARVO meeting.

Our onsite team spoke with Bruce Ksander, PhD, at the 2023 ARVO annual meeting, where he discussed his presentation about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, Kiora Pharmaceuticals showed its investigational drug has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa.

Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).

Nanoscope Therapeutics Inc. presented key data at the ARVO 2023 annual meeting regarding their from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010, which has received both orphan drug and fast track designations from the FDA.

Earlier this year, Théa Pharma Inc. completed the acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. Those products are not impacted by Akorn’s recall of all of its drugs as it ceases all operations.